Anticancer properties of the fatty acid synthase inhibitor TVB-3166 on oral squamous cell carcinoma cell lines
Objective: Fatty acid synthase (FASN) is overexpressed in various human cancers, including oral squamous cell carcinoma (OSCC). TVB-3166 is a novel FASN inhibitor that has shown antitumor activity and potential clinical relevance. This study aimed to evaluate the effects of TVB-3166 on OSCC cell lines.
Materials and Methods: The OSCC cell line SCC-9, modified to express ZsGreen (SCC-9 ZsG), along with its metastatic derivative LN-1A, were used to assess the anticancer properties of TVB-3166. Cell viability was measured using MTT assays, and proliferation was assessed by cell counting in a Neubauer chamber. Apoptosis and cell cycle progression were analyzed by Annexin V-PE/7-ADD-PerCP labeling and PI staining, respectively. Cell migration was evaluated using scratch assays, and cell adhesion was measured using myogel. The expression of FASN, p-AKT, CPT1-α, and epithelial-mesenchymal transition (EMT) markers was determined by Western blotting.
Results: Treatment with TVB-3166 significantly reduced cell viability and proliferation, induced cell cycle arrest and apoptosis, and increased cell adhesion to myogel in both OSCC cell lines. Additionally, TVB-3166 inhibited SCC-9 ZsG cell migration.
Conclusion: Our findings demonstrate that TVB-3166 exerts anticancer effects on both SCC-9 ZsG and its metastatic derivative LN-1A, suggesting its potential as a therapeutic agent for OSCC. Further investigation in preclinical models is warranted to explore its clinical potential.